vs
Side-by-side financial comparison of Webull Corp (BULL) and Esperion Therapeutics, Inc. (ESPR). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $131.5M, roughly 1.3× Webull Corp). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 46.3%).
Webull Corporation, often stylized as simply Webull, is a US-based financial services holding company headquartered in St. Petersburg, Florida. It provides an electronic trading platform of the same name.
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
BULL vs ESPR — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $131.5M | $168.4M |
| Net Profit | $-28.3M | — |
| Gross Margin | — | — |
| Operating Margin | -16.3% | 50.6% |
| Net Margin | -21.5% | — |
| Revenue YoY | 46.3% | 143.7% |
| Net Profit YoY | -144.3% | — |
| EPS (diluted) | — | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $168.4M | ||
| Q3 25 | — | $87.3M | ||
| Q2 25 | $131.5M | $82.4M | ||
| Q1 25 | — | $65.0M | ||
| Q4 24 | — | $69.1M | ||
| Q3 24 | — | $51.6M | ||
| Q2 24 | $89.9M | $73.8M | ||
| Q1 24 | — | $137.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | $-31.3M | ||
| Q2 25 | $-28.3M | $-12.7M | ||
| Q1 25 | — | $-40.5M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-29.5M | ||
| Q2 24 | $-11.6M | $-61.9M | ||
| Q1 24 | — | $61.0M |
| Q4 25 | — | 50.6% | ||
| Q3 25 | — | -11.4% | ||
| Q2 25 | -16.3% | 8.6% | ||
| Q1 25 | — | -34.0% | ||
| Q4 24 | — | -6.4% | ||
| Q3 24 | — | -31.0% | ||
| Q2 24 | -11.4% | 3.5% | ||
| Q1 24 | — | 52.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | -35.9% | ||
| Q2 25 | -21.5% | -15.4% | ||
| Q1 25 | — | -62.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -57.2% | ||
| Q2 24 | -12.9% | -83.9% | ||
| Q1 24 | — | 44.3% |
| Q4 25 | — | $0.32 | ||
| Q3 25 | — | $-0.16 | ||
| Q2 25 | — | $-0.06 | ||
| Q1 25 | — | $-0.21 | ||
| Q4 24 | — | $-0.14 | ||
| Q3 24 | — | $-0.15 | ||
| Q2 24 | — | $-0.33 | ||
| Q1 24 | — | $0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $476.7M | $167.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $751.6M | $-302.0M |
| Total Assets | $2.6B | $465.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $167.9M | ||
| Q3 25 | — | $92.4M | ||
| Q2 25 | $476.7M | $86.1M | ||
| Q1 25 | — | $114.6M | ||
| Q4 24 | — | $144.8M | ||
| Q3 24 | — | $144.7M | ||
| Q2 24 | — | $189.3M | ||
| Q1 24 | — | $226.6M |
| Q4 25 | — | $-302.0M | ||
| Q3 25 | — | $-451.4M | ||
| Q2 25 | $751.6M | $-433.5M | ||
| Q1 25 | — | $-426.2M | ||
| Q4 24 | — | $-388.7M | ||
| Q3 24 | — | $-370.2M | ||
| Q2 24 | $-2.9B | $-344.2M | ||
| Q1 24 | — | $-294.3M |
| Q4 25 | — | $465.9M | ||
| Q3 25 | — | $364.0M | ||
| Q2 25 | $2.6B | $347.1M | ||
| Q1 25 | — | $324.0M | ||
| Q4 24 | — | $343.8M | ||
| Q3 24 | — | $314.1M | ||
| Q2 24 | — | $352.3M | ||
| Q1 24 | — | $373.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $272.1M | $45.2M |
| Free Cash FlowOCF − Capex | $271.7M | — |
| FCF MarginFCF / Revenue | 206.6% | — |
| Capex IntensityCapex / Revenue | 0.3% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $45.2M | ||
| Q3 25 | — | $-4.3M | ||
| Q2 25 | $272.1M | $-31.4M | ||
| Q1 25 | — | $-22.6M | ||
| Q4 24 | — | $-35.0M | ||
| Q3 24 | — | $-35.3M | ||
| Q2 24 | — | $-7.2M | ||
| Q1 24 | — | $53.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $271.7M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-35.5M | ||
| Q2 24 | — | $-7.3M | ||
| Q1 24 | — | $53.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 206.6% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -68.7% | ||
| Q2 24 | — | -9.9% | ||
| Q1 24 | — | 39.0% |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | 0.3% | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.88× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BULL
Segment breakdown not available.
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
